M&A deals, company strategies, pipeline updates and more
Follow our coverage of the 2019 J.P. Morgan Healthcare Conference in San Francisco
The FDA cleared Ossio’s family of bio-integrative bone pins, which secure broken bones while leaving no permanent hardware behind.
GE Healthcare and Vanderbilt University are developing diagnostics that use AI to predict both efficacy and side effects of cancer immunotherapies.
PQ Bypass gathered $60 million in financing to move its minimally invasive tech for circumventing long blockages in leg arteries caused by PAD.
What can you expect from M&A, IPOs and VC raises in 2019? We spoke to execs at the J.P. Morgan Healthcare Conference this week to find out.
At JPM, Propeller Health closed its $225 million buyout with ResMed and launched a partnership with Walgreens for in-app prescription refills.
Roche’s VP of global oncology strategy, Cindy Perettie, will become the next CEO of Foundation Medicine, which it acquired last year for $2.4 billion.
Pear Therapeutics posted $64 million in new funding on the heels of an FDA clearance for its prescription software to treat opioid addiction.
Reva Medical expanded its operations to seven European countries, while it looks to build up clinical evidence for its bioresorbable stents.
SAN FRANCISCO—Guardant Health has launched a new epigenetic liquid biopsy test for researchers aimed at spotting cancer in its early stages.
The FDA has cleared an insulated organ transport system for shepherding small and pediatric hearts from donors to transplant recipients.